The First Drug That Builds Cancer-Killing Cells Inside Your Body
RiboX just got FDA clearance to test the world's first circular RNA-based therapy that builds CAR-T cells inside the body, no factory required. It's a collision of two massive biotech trends, and the implications for autoimmune disease are enormous.
What If You Didn't Need a Factory to Make Cell Therapy?
CAR-T therapy is one of the most powerful weapons in modern medicine. It takes a patient's immune cells out of the body, engineers them to hunt down specific targets, and infuses them back in. The results in blood cancers have been jaw-dropping.
But the process? It's like sending your car to a custom shop in another state, waiting weeks for it to come back, and hoping nothing went wrong during shipping. The whole thing is slow, expensive, and logistically brutal.
RiboX Therapeutics just got FDA clearance to test a radically different idea: skip the factory entirely. Instead of pulling cells out and engineering them in a lab, their drug delivers instructions directly into the bloodstream and turns the patient's own T cells into cancer-fighters while they're still inside the body. And the instructions aren't written in standard mRNA. They're written in something newer, stranger, and potentially better.
The FDA cleared RiboX's investigational new drug (IND) application for RXIM002 on August 8, 2026. If the company's claims hold up, it's the first circular RNA-based in vivo CAR therapy to reach this milestone anywhere in the world.
That's a mouthful. Let's unpack why it matters.
Circular RNA: mRNA's Tougher Cousin
You probably remember mRNA from its star turn during COVID. Moderna and BioNTech used linear mRNA to teach cells how to recognize the spike protein. It worked brilliantly, but linear mRNA has a shelf-life problem. Think of it like a piece of paper with instructions written on it: the moment it enters a cell, enzymes start chewing it up from the edges. The instructions degrade fast, which means the protein it encodes gets produced in a short burst.
Circular RNA (circRNA) is the same concept, but with one crucial twist: the "paper" has no edges. It's a closed loop, like a rubber band. Without exposed ends, the cell's cleanup enzymes can't easily grab onto it. The result, at least in theory, is longer-lasting protein production from a single dose.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
RiboX's entire platform is built on fully engineered circRNA. The company was founded in 2021 by Drs. Ling-Ling Chen, Dan Peer, and Weiyi Zhang, with operations spanning Shanghai, Princeton, and Rehovot, Israel. They'd already made history once: their other drug, RXRG001, became the first circular RNA therapy of any kind to get FDA IND clearance back in October 2024. That one targets a condition where radiation damages salivary glands.
RXIM002 is their second act, and it's far more ambitious.
How RXIM002 Actually Works
The drug comes packaged in targeted lipid nanoparticles (tLNPs), which are essentially tiny fat bubbles designed to find and enter specific cells. Picture a delivery drone that knows exactly which doorstep to land on.
Once inside a T cell, the circular RNA gets translated into a CD19-targeting CAR, a synthetic receptor that locks onto CD19, a protein found on the surface of B cells. The T cell is now a CAR-T cell, programmed to hunt down and destroy B cells.
Why would you want to destroy your own B cells? Because in autoimmune diseases, rogue B cells produce antibodies that attack the body's own tissues. Wipe out those B cells, and you essentially hit the reset button on the immune system. It's a strategy borrowed from the cancer playbook, repurposed for autoimmunity.
The key distinction: because circRNA is non-integrating (it doesn't insert itself into your DNA), the effect is designed to be strong but temporary. RiboX is aiming for an immune reset, not permanent genetic reprogramming. For autoimmune conditions, that's actually the ideal profile. You want to clear the bad actors and let the immune system rebuild cleanly.
The Target: A Disease That Keeps Coming Back
RXIM002's first target is autoimmune cytopenias, conditions where the immune system destroys the body's own blood cells. The Phase 1 trial, called POPULUS-1, will initially enroll patients with relapsed or refractory immune thrombocytopenia (ITP), a disorder where antibodies attack platelets and leave patients vulnerable to dangerous bleeding.
Current treatments for ITP follow a frustrating pattern. Doctors start with corticosteroids and intravenous immunoglobulin (IVIG). Many patients respond initially, but corticosteroids come loaded with side effects, and relapse rates are high. When first-line therapy fails, options include rituximab (a B-cell-depleting antibody), drugs that boost platelet production, or even surgical removal of the spleen. None of these are cures. They're management strategies for a disease that often keeps circling back.
That cycle of treat, relapse, escalate is exactly the kind of unmet need that makes a fundamentally new approach worth testing.
What RiboX Has Shown So Far
The company's preclinical data, while still early, paints an encouraging picture across multiple species. In lab studies, RXIM002 successfully generated CAR expression in human T cells. In mouse models, it drove B-cell depletion. A xenograft model (where human tumors are grown in mice) showed tumor remission. And in cynomolgus monkeys, the drug achieved measurable B-cell reduction.
RiboX also submitted data from investigator-initiated trials conducted in China, and the FDA apparently liked what it saw. The agency permitted an accelerated dose-titration scheme and even greenlit development of a subcutaneous formulation, which could eventually mean patients get injections under the skin instead of through an IV. That's a meaningful convenience signal for a therapy aimed at chronic autoimmune disease.
POPULUS-1 will evaluate safety, pharmacokinetics (how the drug moves through the body), pharmacodynamics (what it does once there), and early signs of efficacy. The key readouts to watch will be whether researchers can detect circulating CAR-T cells, how quickly and deeply B cells get depleted, and whether autoantibody levels drop.
A Race With Very Few Runners (For Now)
RiboX isn't the only company trying to build CAR-T cells inside the body. Capstan Therapeutics is arguably the most direct competitor in the autoimmune space; it initiated a Phase 1 trial of its lead asset CPTX2309 for autoimmune disease in 2025. Other players like Interius BioTherapeutics and Umoja Biopharma are developing in vivo CAR platforms too, though their public focus has leaned more toward oncology so far.
What sets RiboX apart is the circular RNA payload. Everyone else in the in vivo CAR race is using either linear mRNA or viral vectors to deliver instructions. CircRNA is a different bet: potentially longer expression, potentially fewer doses, but with far less human data to back it up. As of mid-2026, the entire circRNA therapeutics field has only a handful of programs in human testing. Compare that to linear mRNA, where Moderna and BioNTech have built commercial empires.
RiboX's $110 million in Series B funding (backed by Qiming VP, Boehringer Ingelheim Venture Fund, and Vivo Capital) gives it a financial runway that most circRNA peers can't match.
The Big Questions That Remain
The excitement here is real, but so is the uncertainty. A few things will determine whether RXIM002 becomes a landmark or a footnote:
Does circRNA actually outperform optimized mRNA in humans? The theoretical advantages (longer expression, no free ends for enzymes to chew) are compelling. But head-to-head data in people doesn't exist yet. Linear mRNA companies have had years to optimize their formulations, and they've gotten remarkably good at it.
Can tLNPs reliably hit T cells in vivo? Targeting specific cell types with lipid nanoparticles inside a living human is orders of magnitude harder than doing it in a petri dish. If the nanoparticles end up in the liver (where LNPs naturally tend to accumulate) instead of T cells, the therapy won't work as intended.
Is transient expression enough? RiboX is betting that a temporary wave of CAR-T activity can reset the immune system in autoimmune disease. If the effect fades too fast, patients might relapse. If it lasts too long, safety concerns emerge. Finding the Goldilocks zone will be critical.
Safety in humans. This is a first-in-class therapy using a relatively novel RNA modality. The preclinical package looks solid, but the history of biotech is littered with drugs that looked great in monkeys and failed in people.
Why This Moment Matters
Zoom out, and RXIM002 sits at the intersection of two of the most exciting trends in biotech: next-generation RNA medicines and in vivo cell therapy. Each of those fields is interesting on its own. Together, they represent a potential paradigm shift in how we treat autoimmune disease.
Traditional CAR-T manufacturing takes weeks, costs hundreds of thousands of dollars per patient, and requires specialized facilities. If in vivo approaches work, you could theoretically treat patients with an injection at a regular clinic. No apheresis. No clean rooms. No three-week wait while your cells get engineered somewhere else.
We're still in the "if" stage, and the POPULUS-1 trial will be one of the most closely watched early-phase studies in the autoimmune space. But the FDA's willingness to clear this IND, and to permit an accelerated dose scheme on top of it, suggests the agency sees enough promise to let RiboX take its shot.
The circular RNA era is no longer theoretical. It just got its second IND. And this time, the ambition is much, much bigger.
Deals & M&A
4 min read
Sandoz Is Buying Its Biosimilar Future From China
Sandoz just committed up to $322 million to license biosimilars from a Chinese company most people have never heard of. The deal with Shanghai Henlius signals something bigger: China's biologics ecosystem has gone from follower to supplier for the world's largest biosimilar company.
